Patients with the AA genotype and receiving warfarin following cardiac valve replacement may have a decreased risk of bleeding at therapeutic INR as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of bleeding while on warfarin therapy.